All In Biotech

Drug Trial Radar · NCT05941936

A Clinical Study on LM103 for the Treatment of Advanced Solid Tumors

An Exploratory Clinical Study Evaluating the Safety, Tolerance, Immune Response, and Initial Efficacy of Autologous Tumor Infiltrating Lymphocytes (TILs) LM103 Injection in Patients With Advanced Solid Tumors

Last checked: Nov 20, 2026Latest source record: Jul 12, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

5

Planned (sponsor's estimate)

Start

May 19, 2023

Primary completion

Feb 2025

Study completion Feb 2026

Sponsor

Sponsor type
Industry
First posted
Jul 12, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is an open exploratory clinical study to evaluate the safety, tolerance, immune response, and initial efficacy of autologous tumor infiltrating lymphocyte LM103 injection in advanced solid tumor patients . The research treatment includes fludarabine and cyclophosphamide, autologous tumor infiltrating lymphocytes (TILs) infusion, and IL-2 therapy.

Conditions

  • Solid Tumor

Interventions

  • LM103Biological

    Fresh tumor samples will be resected from enrolled patients. Autologous TILs will be extracted and reinfused to corresponding patients after ex vivo stimulation, activation and extensive expansion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse events (AE), Serious adverse event (SAE) and immune related adverse events (irAE)Time frame: through study completion, an average of 1 year estimate

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Tianjin Beichen Hospital

    Tianjin, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.